Company
L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
Rius Medical mission is to make its proprietary highly innovative platform available at 3 years to pharmaceutical and biotech partners - Proprietary cell lines for drug delivery. Engineer stem cells for next generation therapeutics as core business.
Waldachtal, Baden-Württemberg, Germany
Send a message
Anglais
Anglais
Cell & Gene Therapy will shape the future of medicine, when novel technologies proceed beyond the primary goals of safety and efficacy. Uneconomical manufacturing is an industry challenge and represents a major roadblock to the sustainable commercialisation of cellular products.
The solution, Rius Medical technology engineers stem cells into therapeutic products. Offering a Business-to-Business solution to U.S. based company Rubius Therapeutics and France-based Erytech...
Cell & Gene Therapy will shape the future of medicine, when novel technologies proceed beyond the primary goals of safety and efficacy. Uneconomical manufacturing is an industry challenge and represents a major roadblock to the sustainable commercialisation of cellular products.
The solution, Rius Medical technology engineers stem cells into therapeutic products. Offering a Business-to-Business solution to U.S. based company Rubius Therapeutics and France-based Erytech Pharma for upgraded red blood cells that do more than simply carry oxygen. For example Erytech Pharma’s therapeutic product is Phase III approved for Acute Lymphoblastic Leukemia and Phase II approved for Pancreatic Cancer.
Rius Medical is seeking a 30.000 euro financing such as a Convertible Loan of 30.000 euro, at a discounted rate of 0,50 euro per share, to help bridge the 2-3 months time for medifundo to bring 300.000 euro equity capital if not 600.000 euro.
Rius Medical implements innovation targeting Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes, all within one platform technology!
Beyond providing solutions for global healthcare’s biggest cost drivers, an EXIT opportunity at 3 years for early investors joining this Series A investment round of up to 1 million euro and pre-money valuation at 4 million euro will result in EUR 54 million financial benefit for FIVE products or EUR 10,5 million financial benefit for TWO products at 3 years to early investors.
1
Followers
Start in 31 August 2016
31 August 2016
registration with the commercial register of Stuttgart local court under folio HRB 757947
to be continued ...